NCT00774904

Brief Summary

Plasma adiponectin concentration is inversely associated with renal function. There is little literature on adiponectin levels and regulation by antihypertensive medication with an angiotensin II-receptor blocker (ARB), especially in subjects with type 2 diabetes in different stage of chronic kidney disease (CKD).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
80

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Apr 2007

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2007

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2007

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2007

Completed
12 months until next milestone

First Submitted

Initial submission to the registry

October 16, 2008

Completed
1 day until next milestone

First Posted

Study publicly available on registry

October 17, 2008

Completed
Last Updated

October 20, 2008

Status Verified

October 1, 2008

Enrollment Period

6 months

First QC Date

October 16, 2008

Last Update Submit

October 17, 2008

Conditions

Diabetic Nephropathy

Keywords

Type 2 DiabetesDiabetic NephropathyGlucose MetabolismAngiotensin II Type 1 Receptor Blockers

Outcome Measures

Primary Outcomes (1)

  • GFR, HbA1c and the adiponectin concentration

    6 month

Interventions

LosartanDRUG

Angiotensin II Type 1 Receptor Blockers

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Type 2 diabetic nephropathy
  • CKD at stage 1\~4

You may not qualify if:

  • Type 1 diabetes or nondiabetic renal disease
  • An elevated plasma K level.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Shanghai No.3 people's hospital

Shanghai, 201900, China

Location

Related Publications (1)

  • Pan Y, Qiao QY, Pan LH, Zhou DC, Hu C, Gu HF, Fu SK, Liu XL, Jin HM. Losartan reduces insulin resistance by inhibiting oxidative stress and enhancing insulin signaling transduction. Exp Clin Endocrinol Diabetes. 2015 Mar;123(3):170-7. doi: 10.1055/s-0034-1395658. Epub 2014 Dec 11.

    PMID: 25502581DERIVED

MeSH Terms

Conditions

Diabetic NephropathiesDiabetes Mellitus, Type 2

Interventions

Losartan

Condition Hierarchy (Ancestors)

Kidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesDiabetes ComplicationsDiabetes MellitusEndocrine System DiseasesGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

Biphenyl CompoundsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsOrganic ChemicalsImidazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsTetrazoles

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

October 16, 2008

First Posted

October 17, 2008

Study Start

April 1, 2007

Primary Completion

October 1, 2007

Study Completion

November 1, 2007

Last Updated

October 20, 2008

Record last verified: 2008-10

Locations

CN(1)